Skip to content
What if the key to curing complex diseases lies not in animals, but in human cells? Discover how cutting-edge human biology models are revolutionizing drug discovery and slashing costly late-stage failures.
Imagine investing years and millions into a drug candidate, only to see it fail in late-stage clinical trials. This is the harsh reality in drug discovery today, where 90-95% of candidates never make it to market. The root cause? A fundamental disconnect between preclinical models and human biology1.
Traditional drug development has long relied on animal models and immortalised cell lines. While these tools have been invaluable, they often fail to capture the intricate complexity of human diseases such as Alzheimer’s or Parkinson’s. These models provide only an approximation, leading to costly failures when drugs that seemed promising in the lab don’t perform in humans. Moreover, unpredicted toxicities, like mitochondrial dysfunction causing cardiotoxicity, frequently emerge late in development, underscoring the limitations of current preclinical testing.
The solution lies in shifting towards human-centric models, particularly those derived from human induced pluripotent stem cells (iPSCs). These cells offer a renewable and scalable source of functional human cells, enabling researchers to study disease mechanisms and drug responses in a context that closely mirrors human physiology. The U.S. Food and Drug Administration’s recent draft guidance encourages the adoption of such physiologically relevant models, signaling a pivotal shift away from animal testing towards more predictive human-based systems.
However, adopting human cell models is not without challenges. Ensuring reproducibility remains a major hurdle, as variability between cell batches, laboratories, and donors can obscure true biological effects. Standardising these models across the industry is crucial, especially as drug discovery becomes more collaborative and data-driven. This standardisation is also vital for harnessing artificial intelligence, which depends heavily on high-quality, consistent biological data to predict drug behaviour and identify new targets effectively1.
Scaling this human-centric approach is a formidable task. The pharmaceutical industry currently utilises millions of animal models and trillions of cell lines annually. Transitioning to human models requires advanced manufacturing capabilities to produce billions of cells without compromising quality or affordability. Yet, this shift is driven not only by ethical considerations but by the urgent need for more predictive and reliable drug development tools.
By embracing human biology models, the pharmaceutical industry can improve clinical translation, reduce costly failures, and ultimately bring safer, more effective treatments to patients faster. For laboratory managers, scientists, and quality professionals, this evolution signals a call to adapt workflows, invest in standardisation, and collaborate across disciplines. The future of drug discovery hinges on bridging the gap between biology and technology—starting with models that truly reflect the human condition.
